...
首页> 外文期刊>Clinical transplantation. >Renal outcomes of simultaneous liver-kidney transplantation compared to liver transplant alone for candidates with renal dysfunction
【24h】

Renal outcomes of simultaneous liver-kidney transplantation compared to liver transplant alone for candidates with renal dysfunction

机译:肾功能不全候选人同时进行肾脏-肾脏移植的肾结局与单纯肝移植相比

获取原文
获取原文并翻译 | 示例

摘要

It is unclear whether a concomitant kidney transplant grants survival benefit to liver transplant (LT) candidates with renal dysfunction (RD). We retrospectively studied LT candidates without RD (n=714) and LT candidates with RD who underwent either liver transplant alone (RD-LTA; n=103) or simultaneous liver-kidney transplant (RD-SLKT; n=68). RD was defined as renal replacement therapy (RRT) requirement or modification of diet in renal disease (MDRD)-glomerular filtration rate (GFR) <25mL/min/1.73m(2). RD-LTAs had worse one-yr post-transplant survival compared to RD-SLKTs (79.6% vs. 91.2%, p=0.05). However, RD-LTA recipients more often had hepatitis C (60.2% vs. 41.2%, p=0.004) and more severe liver disease (MELD 37.9 +/- 8.1 vs. 32.7 +/- 9.1, p=0.0001). Twenty RD-LTA recipients died in the first post-transplant year. Evaluation of the cause and timing of death relative to native renal recovery revealed that only four RD-LTA recipients might have derived survival benefit from RD-SLKT. Overall, 87% of RD-LTA patients recovered renal function within onemonth of transplant. Oneyr after RD-LTA or RD-SLKT, serum creatinine (1.5 +/- 1.2mg/dL vs. 1.4 +/- 0.5mg/dL, p=0.63) and prevalence of stage 4 or 5 chronic kidney disease (CKD; 5.9% vs. 6.8%, p=0.11) were comparable. Our series provides little evidence that RD-SLKT would have yielded substantial short-term survival benefit to RD-LTA recipients.
机译:尚不清楚同时进行的肾脏移植能否为患有肾功能不全(RD)的肝移植(LT)候选者带来生存益处。我们回顾性研究了无RD的LT候选人(n = 714)和有RD的LT候选人单独进行肝移植(RD-LTA; n = 103)或同时进行了肝肾移植(RD-SLKT; n = 68)。 RD定义为肾脏替代疗法(RRT)的要求或肾脏疾病(MDRD)中饮食的修改-肾小球滤过率(GFR)<25mL / min / 1.73m(2)。与RD-SLKT相比,RD-LTA的一年移植后生存期更差(79.6%对91.2%,p = 0.05)。但是,RD-LTA接受者更常患有丙型肝炎(60.2%比41.2%,p = 0.004)和更严重的肝脏疾病(MELD 37.9 +/- 8.1 vs. 32.7 +/- 9.1,p = 0.0001)。在移植后的第一年,有20名RD-LTA接收者死亡。相对于天然肾脏恢复的死亡原因和死亡时间的评估显示,只有四位RD-LTA接受者可能从RD-SLKT获得了生存益处。总体而言,有87%的RD-LTA患者在移植后1个月内恢复了肾功能。 RD-LTA或RD-SLKT后一年级,血清肌酐(1.5 +/- 1.2mg / dL vs. 1.4 +/- 0.5mg / dL,p = 0.63)和4或5期慢性肾脏病患病率(CKD; 5.9 %vs. 6.8%,p = 0.11)是可比的。我们的系列几乎没有证据表明RD-SLKT将为RD-LTA接受者带来实质性的短期生存利益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号